Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice

Filippo De Marinis, Massimo Barberis, Vito Barbieri, Alfonso Marchianò, Stefano Gasparini, Maria Rita Migliorino, Giampiero Romano, Francesca Spinnato, Fabiana Vitiello, Cesare Gridelli

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: In the era of personalized cancer therapy, the sampling of adequate tumor tissue for histologic diagnosis and genomic profiling is crucial, not only at the initial diagnosis but also in the event of resistant and recurrent disease when sequential biopsies may be required to evaluate somatic mutations and histologic changes. Areas covered: The identification of genetic driver alterations led to the selection of patients who are most likely to benefit from epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) and rat osteosarcoma (ROS-1) tyrosine kinase inhibitors; on the other hand, in the absence of oncogenic alterations, platinum-based doublet chemotherapy regimens were the cornerstone of treatment. However, the advent of immunotherapy has widely changed the first-line treatment. Expert commentary: An Italian Experts Panel Meeting was held to discuss on recommendations for diagnosis (optimization of the cyto/histologic tumor sample issue and management of tissue to molecular evaluation) and immunotherapy as first-line treatment of patients with advanced non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)217-228
Number of pages12
JournalExpert Review of Respiratory Medicine
Volume13
Issue number3
DOIs
Publication statusPublished - Mar 4 2019

Keywords

  • Diagnosis
  • first-line treatment
  • immunotherapy
  • non-small-cell lung cancer
  • PD-L1 immunohistochemistry

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice'. Together they form a unique fingerprint.

Cite this